Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 51 clinical trials
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome

potent protease inhibitor that can inhibit the proteases kallikrein 5, 7 and 14 all recognised as up-regulated and causing the disease state in Netherton syndrome patients. Patients will be

  • 24 Mar, 2022
  • 1 location
Consequences of Mutations in the SPG7 Gene at the Heterozygous State

Paraplegin, encoded by the SPG7 gene, is an ATP-dependent mAAA protease located in the inner mitochondrial membrane. Its function is not fully understood. Mutations in the SPG7 gene are

  • 07 Jan, 2022
  • 1 location
The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden

study is to assess whether Camostat, a serine protease inhibitor available in an oral formulation has the potential to be studied as an antiviral drug in a large scale ambulatory setting to prevent

  • 02 Sep, 2021
  • 1 location
Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) (LANA-FXII)

This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to assess the effects and safety of Lanadelumab in patients with FXII-associated cold autoinflammatory syndrome (FACAS).

  • 25 Mar, 2022
  • 1 location
Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

The purpose of this study is to test the efficacy of an oral, nutrient intervention containing the bioactive components of fish oil to promote healing of chronic venous leg ulcers (CVLUs) by reducing the chronic inflammation at wound sites that prevents healing progression. If this systemic, nutrient intervention is found …

  • 27 Apr, 2022
  • 1 location
The Late Presenter Treatment Optimisation Study (LAPTOP)

HIV: The Boosted Protease Inhibitor combination (PI) which is a combination tablet containing: darunavir, cobicistat, emtricitabine and tenofovir alafenamide. It was approved for use in Europe

opportunistic infection
hiv viral load
integrase inhibitors
  • 16 May, 2022
  • 44 locations
68Ga-FAPI PET/MR for Atherosclerosis

A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade

carotid atherosclerosis
  • 17 Sep, 2021
  • 1 location
HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

including NNRTI resistance. The other ARV medication (protease inhibitor, entry inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and NNRTI, will not be changed.

  • 03 Feb, 2021
  • 2 locations
Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients (UTI-RTOM-NPC)

This is a phase 3, open-label, multicenter, randomized controlled phase III clinical trial. The purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease inhibitor, in

  • 26 Feb, 2022
  • 1 location
68Ga-FAPI PET/CT in Malignant Tumors

Fibroblast-activation protein (FAP) is a type transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of

pet/ct scan
primary cancer
  • 12 Sep, 2021
  • 1 location